Golimumab (Simponi) for Inflammatory Arthritis (vol 51, pg 55, 2009)

被引：0

|

作者：

不详

机构：

来源：

MEDICAL LETTER ON DRUGS AND THERAPEUTICS | 2009年 / 51卷 / 1317期

关键词：

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

收藏

页码：60 / 60

页数：1

相关论文

共 50 条

[1] Utilization Pattern of Golimumab (Simponi®) in Patients with Inflammatory Arthritis in Real-Life Clinical Practice in Canada
Abbas, Amir
Monfared, Tahami
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2012, 21 : 41 - 41
[2] Introduction (vol 55, pg 1, 2009)
Baldwin, J. Timothy
ASAIO JOURNAL, 2009, 55 (03) : 307 - 307
[3] Bolt (vol 19, pg 51, 2009)
Silliphant, Stirling
SIGHT AND SOUND, 2009, 19 (03): : 96 - 96
[4] Golimumab: A Review in Inflammatory Arthritis
Frampton, James E.
BIODRUGS, 2017, 31 (03) : 263 - 274
[5] Golimumab: A Review in Inflammatory Arthritis
James E. Frampton
BioDrugs, 2017, 31 : 263 - 274
[6] Cimzia (certolizumab pegol), Simponi (golimumab) The next generation of monoclonal antibody treatment for rheumatoid arthritis
Nolan, Mark
EJHP PRACTICE, 2010, 16 (06): : 52 - 53
[7] The constraints of terminology (vol 51, pg 87, 2009)
Baxter, Peter
DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY, 2009, 51 (03): : 247 - 247
[8] Innovation and competition policy (vol 1, pg 55, 2009)
Goto, A.
JAPANESE ECONOMIC REVIEW, 2009, 60 (03) : 405 - 405
[9] When a Statin Fails (vol 51, pg 58, 2009)
不详
MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2009, 51 (1319): : 68 - 68
[10] Vancomycin Dosing and Monitoring (vol 51, pg 25, 2009)
不详
MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2009, 51 (1310): : 32 - 32

← 1 2 3 4 5 →